Aclaris Therapeutics, Inc. (0H8T.L)
USD 3.14
(6.34%)
USD 3.14
(6.34%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.07 Million USD | 95.8% |
| 2022 | 1.57 Million USD | -27.72% |
| 2021 | 2.17 Million USD | -79.61% |
| 2020 | 10.65 Million USD | 198.49% |
| 2019 | 3.56 Million USD | -88.07% |
| 2018 | 29.91 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.36 Million USD | -20.33% |
| 2024 Q1 | 2.97 Million USD | -3.35% |
| 2023 Q2 | 1.9 Million USD | -3.4% |
| 2023 Q1 | 1.97 Million USD | 25.48% |
| 2023 FY | 3.07 Million USD | 95.8% |
| 2023 Q4 | 3.07 Million USD | 67.61% |
| 2023 Q3 | 1.83 Million USD | -3.63% |
| 2022 Q2 | 1.82 Million USD | -9.68% |
| 2022 Q1 | 2.01 Million USD | -7.23% |
| 2022 Q3 | 1.61 Million USD | -11.15% |
| 2022 FY | 1.57 Million USD | -27.72% |
| 2022 Q4 | 1.57 Million USD | -2.91% |
| 2021 FY | 2.17 Million USD | -79.61% |
| 2021 Q2 | 10.73 Million USD | 0.36% |
| 2021 Q1 | 10.69 Million USD | -21.07% |
| 2021 Q4 | 2.17 Million USD | -8.85% |
| 2021 Q3 | 2.38 Million USD | -77.79% |
| 2020 Q2 | 13.82 Million USD | -1.08% |
| 2020 FY | 10.65 Million USD | 198.49% |
| 2020 Q4 | 13.54 Million USD | -0.86% |
| 2020 Q3 | 13.66 Million USD | -1.16% |
| 2020 Q1 | 13.97 Million USD | 291.62% |
| 2019 Q4 | 3.56 Million USD | -89.43% |
| 2019 Q3 | 33.77 Million USD | -3.2% |
| 2019 Q2 | 34.89 Million USD | 5.51% |
| 2019 Q1 | 33.07 Million USD | 10.55% |
| 2019 FY | 3.56 Million USD | -88.07% |
| 2018 Q4 | 29.91 Million USD | 0.0% |
| 2018 FY | 29.91 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 87.387% |
| Dynavax Technologies Corporation | 252.41 Million USD | 98.782% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 90.74% |
| Perrigo Company plc | 3.63 Billion USD | 99.915% |
| Illumina, Inc. | 1.48 Billion USD | 99.794% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.99% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -207.4% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.962% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.976% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 98.231% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.886% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 86.941% |
| Waters Corporation | 2.3 Billion USD | 99.867% |
| Biogen Inc. | 7.18 Billion USD | 99.957% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 90.828% |
| Evolus, Inc. | 120.35 Million USD | 97.446% |
| Adicet Bio, Inc. | 17.7 Million USD | 82.636% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 91.71% |
| bluebird bio, Inc. | 224.41 Million USD | 98.63% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.387% |
| FibroGen, Inc. | 89.69 Million USD | 96.573% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.888% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 5.083% |
| Homology Medicines, Inc. | 43.17 Million USD | 92.88% |
| Geron Corporation | 35.05 Million USD | 91.23% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.869% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.207% |
| Myriad Genetics, Inc. | 130.9 Million USD | 97.652% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -228.419% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 96.823% |
| Zoetis Inc. | 6.56 Billion USD | 99.953% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 30.168% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.844% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.482% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.576% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 91.009% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.78% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 93.272% |
| Verastem, Inc. | 40.08 Million USD | 92.331% |
| Nektar Therapeutics | 112.62 Million USD | 97.271% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 98.274% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.729% |
| OPKO Health, Inc. | 222.03 Million USD | 98.616% |
| Exelixis, Inc. | 189.94 Million USD | 98.382% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 98.81% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 97.637% |
| Imunon, Inc. | 1.13 Million USD | -169.816% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.497% |
| Insmed Incorporated | 1.19 Billion USD | 99.742% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.795% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 94.606% |
| TG Therapeutics, Inc. | 100.11 Million USD | 96.93% |
| Incyte Corporation | 29.16 Million USD | 89.459% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 99.312% |